NIH-Funding

Notice of Correction for PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)

NIH Funding Announcements - Thu, 12/07/2017 - 11:20
Notice NOT-TR-18-012 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Correction to Funding Opportunity Description for RFA-HL-16-025 "NHLBI Emerging Investigator Award (EIA) (R35)"

NIH Funding Announcements - Thu, 12/07/2017 - 11:08
Notice NOT-HL-17-569 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) - Clinical Trial Required

NIH Funding Announcements - Thu, 12/07/2017 - 10:59
Funding Opportunity PAR-18-486 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of award.
Categories: NIH-Funding

NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) - Clinical Trial Not Allowed

NIH Funding Announcements - Thu, 12/07/2017 - 10:59
Funding Opportunity PAR-18-490 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of award.
Categories: NIH-Funding

Notice of Correction to Funding Opportunity Description for RFA-HL-16-024 "NHLBI Outstanding Investigator Award (OIA) (R35)"

NIH Funding Announcements - Thu, 12/07/2017 - 04:25
Notice NOT-HL-17-568 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Interest to Highlight NIDA High-Priority Workforce Development Needs in the Chemistry of Addiction

NIH Funding Announcements - Thu, 12/07/2017 - 02:13
Notice NOT-DA-17-063 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Findings of Research Misconduct

NIH Funding Announcements - Thu, 12/07/2017 - 02:09
Notice NOT-OD-18-113 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01-Clinical Trial Required)

NIH Funding Announcements - Wed, 12/06/2017 - 12:55
Funding Opportunity PAR-18-427 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.
Categories: NIH-Funding

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/06/2017 - 12:04
Funding Opportunity PA-18-484 from the NIH Guide for Grants and Contracts. The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept clinical trials.
Categories: NIH-Funding

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional)

NIH Funding Announcements - Wed, 12/06/2017 - 11:44
Funding Opportunity RFA-DA-18-020 from the NIH Guide for Grants and Contracts. The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.
Categories: NIH-Funding

The NCI Transition Career Development Award (K22 Independent Clinical Trial Required)

NIH Funding Announcements - Wed, 12/06/2017 - 11:14
Funding Opportunity PAR-18-466 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.
Categories: NIH-Funding

The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/06/2017 - 11:14
Funding Opportunity PAR-18-467 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.
Categories: NIH-Funding

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)

NIH Funding Announcements - Wed, 12/06/2017 - 10:21
Funding Opportunity RFA-DA-18-019 from the NIH Guide for Grants and Contracts. The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.
Categories: NIH-Funding

Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01, Clinical Trial Optional)

NIH Funding Announcements - Wed, 12/06/2017 - 10:03
Funding Opportunity PA-18-465 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.
Categories: NIH-Funding

Planning Grant to Develop Phase III Clinical Trials for Lewy Body Dementia (R34 clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/06/2017 - 05:58
Funding Opportunity RFA-NS-18-017 from the NIH Guide for Grants and Contracts. The purpose of this R34 FOA is to provide one year of support for planning activities necessary for initiating a Phase III clinical trial designed to treat patients with Lewy Body Dementias (LBD), which include Dementia with Lewy Bodies and Parkinson's Disease Dementia. Such activities may include identifying trial sites/collaborators, designing trial protocols and procedures, and addressing regulatory approvals.
Categories: NIH-Funding

NICHD Exploratory/Developmental Research Grant (R21 - Clinical Trial Optional)

NIH Funding Announcements - Wed, 12/06/2017 - 05:54
Funding Opportunity PA-18-482 from the NIH Guide for Grants and Contracts. The NICHD Exploratory/Developmental Grant program supports exploratory and developmental research projects that fall within the NICHD mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Categories: NIH-Funding